Clinical trial
A Phase II Study of Epigenetic Therapy to Overcome Chemotherapy Resistance in…
NCT00404508 · National Institute of Cancerología, Other · Completed
Key facts
| NCT number | NCT00404508 |
|---|---|
| Title | A Phase II Study of Epigenetic Therapy to Overcome Chemotherapy Resistance in Refractory Solid Tumors |
| Official title | A Phase II Study of Epigenetic Therapy With Hydralazine and Magnesium Valproate to Overcome Chemotherapy Resistance in Refractory Solid Tumors |
| Lead sponsor | National Institute of Cancerología, Other |
| Collaborators | Psicofarma, S.A. De C.V. Industry National Council of Science and Technology, Mexico |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Refractory Solid Tumors |
| Intervention type | Drug |
| Interventions | Hydralazine and magnesium valproate |
| Enrollment | 15 |
| Start date | Sep 1, 2005 |
| Completion | Oct 1, 2006 |
| First posted | Nov 28, 2006 |
| Last update posted | Nov 28, 2006 |
| Countries | Mexico |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: